Skip to main content
新赣江 logo

新赣江 — Investor Relations & Filings

Ticker · 920367 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2024-08-27 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920367

About 新赣江

http://www.xgjyy.com/

Jiangxi Xinganjiang Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company's portfolio encompasses chemical active pharmaceutical ingredients (APIs), chemical drug preparations, and traditional Chinese medicine (TCM) formulations. Its core product offerings target therapeutic areas such as cardiovascular and cerebrovascular health, digestive system disorders, and nutritional supplementation. Key products include Ginkgo Biloba extract, Vitamin C, and various gastrointestinal medications. By maintaining an integrated value chain that spans from raw material synthesis to finished dosage forms, the company ensures quality control and supply chain efficiency. It focuses on delivering high-quality healthcare solutions through continuous innovation in pharmaceutical manufacturing and formulation technology.

Recent filings

Filing Released Lang Actions
第三届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of proposals related to the 2024 semi-annual report and a special report on the use of raised funds. The document references the actual reports being disclosed separately on the Beijing Stock Exchange information platform with specific announcement numbers. The document itself does not contain the financial data or the full reports but announces the resolutions passed in the Supervisory Board meeting. The document length is short (1338 characters) and it serves as a meeting resolution announcement rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice, not as the semi-annual report (IR) or any other detailed report.
2024-08-27 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled '2024 年半年度报告摘要' which translates to '2024 Half-Year Report Summary'. It contains detailed financial data for the half-year period ending June 30, 2024, including revenue, net profit, cash flow, and equity structure. It also includes operational details, business model descriptions, shareholder information, and notes on asset restrictions. The document explicitly states it is a summary of the half-year report and references the full half-year report for more details. The length is over 6,000 characters and contains substantive financial data and analysis, not just an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-27 Chinese
第三届董事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the company's third board meeting, including approval of the 2024 semi-annual report and a special report on the use of raised funds. It details meeting attendance, voting results, and references the actual reports being disclosed separately on the exchange platform. The document itself does not contain the financial data or the full report but announces the board's decisions and approvals. This fits the category of Board/Management Information (MANG), as it concerns board meeting resolutions and management decisions rather than the report itself or a regulatory filing. The document length is short (1520 characters), consistent with an announcement rather than a full report.
2024-08-27 Chinese
2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2024 年半年度报告" which translates to "2024 Semi-Annual Report". It contains detailed financial data, accounting policies, business overview, risk factors, and operational results for the period January 1, 2024 to June 30, 2024. The document includes comprehensive financial statements and analysis, typical of an interim or quarterly report. It is not a brief announcement or a certification letter but a full report with substantive financial data and management discussion. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-27 Chinese
董事长、监事会主席、高级管理人员换届公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election and appointment of the company's chairman, supervisory board chairman, and senior management personnel. It details the changes in the board and senior management, including their qualifications and shareholdings. There is no financial data, earnings information, or report publication mentioned. The document is clearly about management changes and governance structure updates. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on personnel changes, confirming it is not a full report or announcement of a report publication.
2024-08-18 Chinese
2024年第一次临时股东大会决议公告
Board/Management Information Classification · 95% confidence The document is titled as a resolution announcement from the 2024 first extraordinary shareholders meeting of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and election of new board members and supervisors. It includes legal opinions on the meeting's validity and lists changes in board and supervisory personnel effective from the meeting date. The content focuses on board and management changes and shareholder meeting resolutions rather than financial results or reports. The document length is 4401 characters, which is relatively short but contains detailed voting results and management changes. This fits the category of Board/Management Information (MANG) as it announces changes in the company's board of directors and senior management following a shareholder meeting. It is not an Annual Report, Audit Report, or Earnings Release, nor is it a simple announcement of a report publication. Therefore, the correct classification is MANG with high confidence.
2024-08-18 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.